Resmed Inc. Stock
Resmed Inc. Stock
Resmed Inc. gained 0.640% compared to yesterday.
Resmed Inc. is currently one of the favorites of our community with 20 Buy predictions and no Sell predictions.
As a result the target price of 256 € shows a positive potential of 26.67% compared to the current price of 202.1 € for Resmed Inc..
Pros and Cons of Resmed Inc. in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Resmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Resmed Inc. | 0.640% | -7.251% | -4.984% | -0.148% | -3.070% | 5.118% | 30.387% |
| Veeva Systems A | -0.380% | -7.092% | 6.751% | -25.488% | -18.251% | -0.641% | -27.406% |
| Thermo Fisher Scientific Inc. | -1.510% | -5.677% | -4.069% | -13.083% | -17.463% | -19.228% | 8.340% |
| Intuitive Surgical Inc | -0.530% | -2.000% | 1.210% | -6.016% | -15.363% | 95.007% | 102.280% |
Comments
ResMed (NYSE:RMD) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its "overweight" rating reaffirmed by analysts at KeyCorp.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for RMD provided by MarketBeat
News
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.
